Shares of Keros Therapeutics (NASDAQ:KROS) added ~22% in the premarket on Thursday after the biotech commenced a review process to evaluate different strategic options, including a potential sale of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback